B cell–derived IL-4 acts on podocytes to induce proteinuria and foot process effacement

Alfred H.J. Kim,1 Jun-Jae Chung,2 Shreeram Akilesh,2 Ania Koziell,3 Sanjay Jain,4 Jeffrey B. Hodgin,5 Mark J. Miller,2 Thaddeus S. Stappenbeck,2 Jeffrey H. Miner,4 and Andrey S. Shaw2,6

1Division of Rheumatology, Department of Internal Medicine, and 2Division of Immunobiology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA. 3Department of Experimental Immunobiology, Division of Transplantation Immunology and Mucosal Biology, King’s College London and Department of Paediatric Nephrology, Evelina Children’s Hospital, London, United Kingdom. 4Renal Division, Washington University School of Medicine, St. Louis, Missouri, USA. 5Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA. 6Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, Missouri, USA.

Introduction

B cell depletion therapies (BCDTs), such as rituximab, are efficacious in numerous immune-mediated diseases, including rheumatoid arthritis and multiple sclerosis (1). Current BCDTs target CD20 and eliminate B cells but not antibody-producing plasma cells because they do not express CD20 (2). Indeed, most autoantibodies remain present after depletion despite clinical response (3), suggesting that B cells may contribute to tissue injury in an antibody-independent manner.

Since the first reports in 2004 of the successful treatment of steroid-sensitive nephrotic syndromes (SSNS), such as minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS), using rituximab (4–6), there are now over 200 publications in the literature. The majority of these are anecdotal reports and small uncontrolled studies, but the consensus today is that BCDTs are likely efficacious for steroid-sensitive, relapsing forms of disease. By definition, autoreactive antibodies and immune complexes are absent in MCD and FSGS (7). Current therapies are based on the idea that immune dysfunction, potentially involving T cells, is involved in the pathogenesis of these diseases, as first proposed by Shalhoub (8). This idea is supported by the responsiveness of most MCD/FSGS patients to immunosuppressive therapies. Furthermore, the clinical observation that some patients with nephrotic syndrome respond to plasmapheresis suggests that a soluble, circulating factor may be responsible (9, 10). The efficacy of BCDTs supports an immune origin of disease for some nephrotic patients. However, a specific mechanism to explain disease pathogenesis is still lacking.

Given the absence of pathogenic antibodies in these diseases, a role for B cells would need to be antibody independent. In recent years, antibody-independent functions have been ascribed to B cells. Mouse models of systemic lupus erythematosus (SLE) demonstrate that B cells are as important as
antigen-presenting cells for autoreactive T cells (11). B cells can also make cytokines that can either promote or inhibit inflammation (12, 13). Cytokines produced by B cells are required for the development of lymph node and ectopic lymphoid follicles, can amplify T cell responses, and can suppress arthritis, colitis, and experimental autoimmune encephalitis in mice (14, 15).

The cardinal pathologic feature of nephrotic diseases is foot process effacement of the glomerular podocyte. The glomerulus houses the glomerular filtration barrier, where a highly differentiated epithelial cell known as the podocyte forms the final cellular barrier for the filtration of blood and generation of urine. Podocytes have a specialized architecture characterized by interdigitating cellular arborizations (foot processes) that form a mesh-like structure on the urinary aspect of the glomerular capillaries. In all cases of active proteinuria, podocytes exhibit a simplification and flattening/retraction of the podocyte foot processes, a finding termed foot process effacement. Given the lack of cellular inflammation or immune complexes in MCD and FSGS, the likeliest scenario for an immunologic cause would be a factor secreted by an immune cell.

In this study, we directly tested whether cytokines produced by B cells could induce podocyte foot process effacement and proteinuria. Using an in vitro assay of podocyte injury, we identified IL-4 as a cytokine capable of stimulating membrane ruffling of podocytes and detachment of podocytes from the basement membrane in vitro. Using a method of in vivo gene delivery, we confirmed that IL-4 is sufficient to induce foot process effacement and proteinuria when overexpressed in mice. To determine whether B cells activated locally in the kidney could make enough IL-4 to induce foot process effacement, we planted a B cell antigen on the glomerular basement membrane (GBM) and showed that antigen-specific B cells could induce foot process effacement in an IL-4-dependent fashion. Finally, we found evidence of IL-4 receptor signaling in the kidneys in some patients with MCD. Taken together, these findings reveal a mechanism for the efficacy of anti–B cell therapies in the treatment of steroid-sensitive nephrotic diseases. These results also suggest that IL-4 is a potential nephrotic factor and therapeutic target.

Results

Rituximab does not bind SMPDL3B in nonfixed cells. It was recently proposed that the effect of rituximab on nephrotic syndrome is not due to B cells but is instead mediated by its off-target binding to sphingomyelin-phosphodiesterase-acid-like-3b (SMPDL3B) expressed on podocytes (16). To confirm the binding of SMPDL3B by rituximab, we overexpressed HA-tagged SMPDL3B in 293T cells that do not endogenously express either CD20 or SMPDL3B. Expression and membrane localization of HA-SMPDL3B were confirmed by immunoblotting and immunofluorescence with HA and SMPDL3B antibodies (Figure 1A and Supplemental Figure 1, A and B; see complete unedited blots in the supplemental material; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.81836DS1). Modeling suggested that the N-terminal HA-tag is spatially separated from the SMPDL3B epitope (156ELWKPW161) reported to be recognized by rituximab (Supplemental Figure 1C).
To mimic the in vivo setting, we incubated nonfixed cells with rituximab and an anti-HA tag antibody. In 293T cells expressing HA-SMPDL3B, staining was detected with an anti-HA antibody but not with rituximab (Figure 1B and Supplemental Figure 2, A and B). Notably, when cells were fixed with paraformaldehyde (PFA) prior to antibody staining, we observed marked binding of rituximab to cells, regardless of SMPDL3B expression (Figure 1B and Supplemental Figure 2, A and B). Similar results were obtained with HeLa cells overexpressing HA-SMPDL3B (Supplemental Figure 3, A and B; see complete unedited blots in the supplemental material). Binding of rituximab to CD20 was confirmed by staining Raji cells (Supplemental Figure 1D). These results suggest that rituximab does not bind to SMPDL3B in vivo and that the binding previously reported is not specific. This suggests that the efficacy of rituximab in nephrotic kidney diseases is not through its ability to bind and directly modulate podocytes. We therefore considered antibody-independent B cell functions.

**IL-4 and IL-13 induced membrane ruffling in cultured podocytes and foot process retraction in kidney fragments in vitro.** B cells secrete a diverse array of cytokines upon activation, including IFN-γ, TNF-α, IL-4, and IL-13 (13, 17–20). Conversely, podocytes express cytokine receptors, including receptors for IFN-γ, TNF-α, IL-4, and IL-13 (21–23). Therefore, we tested individual cytokines for their ability to induce foot process effacement in vitro.
We have proposed that the activation of the small GTPase Rac is the cell biological correlate for foot process effacement in vivo (24, 25). Rac is a member of the Rho family of small G proteins, which also includes Cdc42 and Rho. Rac activation stimulates the formation of actin cytoskeletal structures that are associated with cell migration and membrane ruffling (26). Rac activation in podocytes acutely induces foot process effacement and proteinuria in mice (24, 25).

Cytokines were added to cultured murine podocytes, and differential interference contrast live-cell imaging of individual cells in separate culture dishes was used to evaluate the response. Membrane ruffling was used as a surrogate for Rac activation, and kymograph analysis was used to quantitate membrane ruffling before and after addition of the cytokine (25, 27). IL-4 and, to a lesser extent, IL-13 induced membrane ruffling, while TNF-α and IFN-γ had no effect on membrane ruffling (Figure 2, A and B, and Supplemental Videos 1 and 2). IL-4 stimulated a similar degree of ruffling as EGF, a known activator of Rac (28). The addition of a neutralizing IL-4 antibody abrogated IL-4–induced membrane ruffling (Figure 2B), indicating that the effect was IL-4 specific.

Since cultured podocytes do not form foot processes, we minced murine renal cortices where the glomeruli are located and treated these fragments with cytokines to evaluate for abnormalities in foot process morphology. Using scanning electron microscopy, we found that IL-4 induced severe foot process retractions, podocyte detachment, and exposure of the glomerular capillary wall, while TNF-α did not (Figure 2C). The changes induced by IL-4 were comparable to those induced by EGF and were blocked with anti–IL-4 antibody (Figure 2C). These data confirmed the ability of IL-4 to directly induce podocyte damage in ex vivo renal cortex.
IL-4 overexpression induces proteinuria and IL-4 signaling in the glomerulus in vivo, which is reduced with JAK1/3 inhibition. To evaluate the role of IL-4 in vivo, we expressed IL-4 in mice by injecting a plasmid based on a transposon expression system using hydrodynamic injection (29–31). In this system, the gene of interest integrates into the genome in a site-specific fashion, primarily in hepatocytes, allowing for efficient and high-level expression of the introduced gene (32). Delivery of the IL-4 gene induced marked proteinuria (Figure 3, A and B; see complete unedited blots in the supplemental material) with a severity that directly correlated with serum levels of IL-4 (Figure 3C). No proteinuria was seen when a control targeting vector was administered. Scanning electron microscopy performed on kidneys 3 days after plasmid administration demonstrated blunted foot processes with scattered areas of effacement (Figure 3D). In comparison, the foot processes of podocytes from control mice were normal. These data show that high serum levels of IL-4 via its overexpression in the liver can directly induce podocyte foot process abnormalities and proteinuria in vivo.

IL-4 signals through the IL-4 receptor (IL-4Rα and common-γ chain) to activate the tyrosine kinases JAK1 and JAK3 and subsequently the transcription factor STAT6 (33). Kidney sections obtained from mice 24 hours following mock or IL-4 plasmid administration were stained for pSTAT6 using immunohistochemistry (Figure 3E). IL-4 treatment strongly induced pSTAT6 within podocytes and other glomerular cells, with little to no staining detected in the glomeruli of control mice. Urine was collected 24 hours after plasmid administration. Symbols represent individual mice, and bars represent the mean. Mean ± SEM of 2 experiments, with total of 5 mice/group. *P < 0.008 by 2-tailed Mann-Whitney.

Since IL-4 utilizes the JAK1 and JAK3 kinases for signaling, we tested if JAK1/3 inhibition could block IL-4–induced membrane ruffling in podocytes in vitro and the development of proteinuria in vivo. A small-molecule inhibitor of JAK1 and JAK3, tofacitinib, is approved for the treatment of rheumatoid arthritis (34). Pretreatment of cultured podocytes with the inhibitor significantly decreased membrane ruffling induced by IL-4 (Figure 4, A and B). To assess its effects in vivo, mice were treated with the inhibitor twice daily, starting 1 day prior to IL-4 gene delivery. Treatment with the JAK inhibitor
significantly attenuated the proteinuria induced by IL-4 (Figure 4, C and D; see complete unedited blots in the supplemental material). Thus, JAK1/3 inhibition can block the effects of IL-4 on foot process effacement and proteinuria.

Generation of a B cell–dependent in vivo model of proteinuria. We next wondered if B cells could be activated in the glomerulus and whether they could produce sufficient IL-4 to induce podocyte foot process effacement and proteinuria in vivo. To test this hypothesis, we targeted a B cell antigen to the glomerular capillary wall, followed by an infusion of antigen-specific B cells. We chose the soluble antigen hen egg lysozyme (HEL), as a B cell receptor–specific transgenic mouse exists for it (35). HEL has a high negative log dissociation constant (pKᵢ (~12) that allows it to enter the negatively charged glomerular filtration barrier, but its small size (14 kDa) allowed it to be freely filtered through the GBM. To trap HEL within the glomerular capillary wall, we conjugated it to biotin, allowing us to produce larger tetrameric aggregates using avidin (Figure 5A). The HEL multimers had a molecular weight greater than 120 kDa (Figure 5B; see complete unedited blots in the supplemental material), well above the size exclusion limit (~60–70 kDa) of the glomerular filtration barrier. I.v. injection of avidin/biotin/HEL complexes resulted in trapping of multimers in the GBM within 30 minutes (Figure 5C) and was stable up to a week after injection. HEL multimers were also detected in the liver and spleen (data not shown).

We next tested whether adoptive transfer of polarized antigen-specific B cells could induce proteinuria. B cells were polarized into B effector 2 (Be2) cells by activating them in the presence of Th2-polarized cells (Figure 6A); then they were injected into mice i.v. (13, 36). Within 24 hours, mice became proteinuric, as detected qualitatively using SDS-PAGE of urine samples or quantitatively using a urinary albumin ELISA (Figure 6, B and C; see complete unedited blots in the supplemental material). The proteinuria was transient, peaking between 12 and 24 hours, and specific to IL-4, since transfer of antigen-specific B cells that were IL-4 deficient (IL-4−/−) did not induce proteinuria. IL-4−/− Be2 cells were only deficient in IL-4, and the other cytokines produced were made at the same levels as wild-type B cells (Supplemental Figure 4). Circulating IL-4 was undetectable by ELISA in the mice injected with antigen-specific B cells, suggesting that the effect was due to local B cell activation and release of IL-4 (data not shown). This was supported by 2-photon imaging of B cells in the kidney (37).
After injection of antigen, mice were anesthetized and a kidney was exteriorized. Injection (i.v.) of fluorescent dextran labeled blood vessels and allowed us to identify glomeruli. In the absence of cognate antigen, labeled HEL-specific B cells trafficked rapidly through the glomerular capillaries. In contrast, when antigen was present, B cells entered the glomerular capillaries and arrested their movement within the glomeruli (Figure 6D and Supplemental Videos 3 and 4). B cell arrest within the glomerular capillaries when antigen was present suggests that in situ recognition of antigen leads to B cell activation and cytokine secretion.

Since the activation of B cells within glomeruli could induce inflammatory changes, we performed light and immunofluorescence microscopy to assess for pathologic changes. We observed no obvious morphologic alterations in the glomeruli of proteinuric mice by light microscopy at all time points tested.
In addition, immunofluorescence staining of sections from proteinuric mice showed no detectable immunoglobulin or complement deposition in glomeruli (Figure 7B). Ultrastructural analysis of the glomeruli using scanning electron microscopy confirmed the presence of focal foot process effacement in proteinuric mice, while nonproteinuric control mice had normal foot processes (Figure 7C). Thus, B cells, activated in the kidney, can induce proteinuria and foot process effacement independent of antibodies and immune complexes.

Glomerular STAT6 activation occurs in a subset of MCD patients. STAT6 phosphorylation is specific for signaling by IL-4 and IL-13. To test if pSTAT6 can be detected in humans with nephrotic syndrome, we stained kidney biopsy sections from patients with MCD for STAT6 activation. Since most patients with MCD respond to initial treatment with glucocorticoids, patients are often biopsied only after treatment failure, limiting the availability of naive biopsy tissue. Such patients are also by definition steroid resistant and not likely to be sensitive to BCDTs. Twenty-nine patients with MCD, in which a biopsy was obtained before initiation of treatment, were identified from the Renal Pathology Services at Washington University School of Medicine, the University of Michigan, and King’s College/Evelina Children’s Hospital (Supplemental Table 1). For controls, we stained 23 kidney biopsies obtained for conditions unrelated to nephrotic syndrome (see Methods for diagnoses). Two of the twenty-nine MCD biopsies demonstrated strong glomerular pSTAT6 staining, and eight had weakly positive staining (see Methods for definitions). Of 23 controls, only one showed weakly positive pSTAT6 staining (Figure 8). While this is a small sample, these data support the hypothesis that IL-4 and/or IL-13 may be involved in some patients with MCD.
Discussion

Since the first reports of rituximab in the treatment of nephrotic diseases in 2004, its use has become an important part of the treatment armamentarium, especially for steroid-sensitive and relapsing forms of MCD and FSGS. Since there is no known role for B cells in these diseases, how and why rituximab mediates its efficacy is a mystery. One potential explanation is the ability of rituximab to directly bind to SMPDL3B on the podocyte (16), reversing changes in integrin affinity. Reports that ofatumumab, a CD20 antibody that binds to an epitope distinct from rituximab (38, 39), is also efficacious in patients with steroid-resistant FSGS (6) motivated us to reexamine this question. SMPDL3B, a protein expressed on podocytes but also broadly expressed on monocytes and gut epithelia, was initially proposed to bind to rituximab, as it contains a peptide sequence, in the reverse orientation, to an epitope identified in a screen for rituximab-binding sequences (40). Previous binding assays used fixed samples and amplification steps to visualize staining of podocytes with rituximab, indicating that the binding is weak (16). Our data suggest that the binding is not specific, suggesting that B cell depletion is the mechanism of action.

Figure 8. A subset of minimal change disease patients has activated glomerular STAT6. Representative immunohistochemistry of glomerular pSTAT6 expression in selected MCD patients (described in Supplemental Table 1) and a control. Ten of twenty-nine MCD patients screened demonstrated pSTAT6 staining (untreated MCD, arrows point to stained nuclei). Twenty-two of twenty-three healthy controls had no detectable pSTAT6 staining. Of 29 MCD patient samples stained for pSTAT6, 2 were strongly positive, 8 were weakly positive, and 19 were negative; of 22 controls samples stained for pSTAT6, 1 was weakly positive and 22 were negative ($P = 0.019$). Original magnification, ×400.
Nephrotic diseases, such as MCD and FSGS, are by definition not caused by autoantibodies or by immune complexes. A major diagnostic feature for both MCD and FSGS is foot process effacement. The responsiveness of these diseases to immunosuppressive treatments such as glucocorticoids, calcineurin inhibitors, and mycophenolate has led many to consider these T cell–mediated diseases, even without specific evidence. The efficacy of BCDTs in the treatment of some fraction of cases, however, supports an immune component to these diseases.

In recent years, antibody-independent roles for B cells have emerged as important in several disease models. B cells express MHC class II and are excellent antigen-presenting cells. In mouse models of SLE, depletion of B cells impairs the activation of autoreactive T cells, suggesting that B cells play important roles as antigen-presenting cells (11). Recently, there has been a growing appreciation for the regulatory effects of B cell–derived cytokines, such as IL-10 and IL-35, on attenuating organ-specific autoimmunity in experimental autoimmune encephalitis (14, 15). B cells can also make a wide array of both Th1 and Th2 cytokines both in vitro (41–45) and in vivo (12, 13).

We and others have suggested that an imbalance between the Rac and Rho G proteins underlies the process of foot process effacement (24, 25, 46). Rho functions to maintain large actin structures important for cell adhesion, while Rac functions to stimulate cell migration and membrane ruffling and spreading (25, 26). During injury, Rac becomes active and induces the process of foot process effacement (24). Using this knowledge, we used markers of Rac activation, such as membrane ruffling in cultured podocytes, as a surrogate for foot process effacement. We confirmed the effects of IL-4 on podocytes in situ assay using an assay that we developed using minced renal cortices treated ex vivo with cytokines. Our success using these assays to identify IL-4 suggests that this assay could also be used to screen for the elusive soluble factors that have been speculated to cause nephrotic syndrome (47).

A pathogenic role for cytokine signaling in proteinuric diseases is supported by a recent publication describing a transgenic mouse overexpressing JAK2 in podocytes (48). When crossed with the Akita diabetic nephropathy mouse model infused with angiotensin II, enhanced proteinuria was observed that was largely reversed with JAK2 inhibition. As JAK2 is regulated by cytokines, these data help to link cytokines with foot process effacement.

The role of IL-4 in other glomerular injury models is controversial. It is implicated in the development of proteinuria in models of graft-versus-host disease (49–51), some models of SLE (52, 53), and IgA nephropathy (54–58) but attenuates proteinuria induced by autologous models of nephrototoxic nephritis (59–63). Given that autologous nephrototoxic nephritis relies on immunization against sheep antibody and that IL-4 has direct effects on antibody isotype switching, the role of IL-4 in nephrototoxic nephritis is complex and not solely dependent on its effect on podocytes.

We are not the first to propose a role of IL-4 and IL-13 in nephrotic syndrome. IL-4 is secreted by Th2 helper T cells and associated with atopy, a condition that is highly associated with MCD (64, 65). Transgenic mice expressing IL-4 develop glomerulosclerosis (53, 66–68) and transgenic rats expressing IL-13 develop proteinuria (69). While it was reported previously that podocytes express the IL-4 receptor (IL-4Rα and common γ-chain) and can respond to IL-4 (23), attempts to link IL-4 levels in serum and urine with nephrotic diseases have been largely unrevealing (70, 71). One possibility is that IL-4 is produced locally at levels too low to be detected in blood or urine.

To test whether this was a viable hypothesis, we generated a model that would allow for B cell activation in the glomerulus. This suggested that activated B cells could produce enough IL-4 to induce proteinuria. Notably, we were unable to detect IL-4 in the serum, showing that local IL-4 can be pathogenic. While this may not be the mechanism of disease in humans, it does suggest other potential mechanisms. Recent data show that memory lymphocytes can exist as long-term residents of tissues such as lung and skin and far outnumber the number of lymphocytes circulating in the peripheral immune system (72). These cells often function as cytokine-secreting sentinel cells that respond to pathogens and/or antigens that transit through organs. Little is known yet about memory lymphocytes or innate lymphocytes in kidney, but these specialized cells could be relevant. Finally, polyclonal B cell activators, such as TLR ligands, released during infections and trapped by the glomerulus, could be another potent stimulus of B cell activation (73).

We noted that IL-13 was able to induce some level of membrane ruffling in our in vitro assay. While this is consistent with a previous study in rats showing that IL-13 can induce proteinuria, IL-13 plasmid administration in mice did not induce proteinuria (data not shown). The reason for the difference between
mice and rats remains unknown but may represent species-specific requirements for cytokine-induced proteinuria. Furthermore, the role of IL-13 in SSNS patients remains unclear (74), as glucocorticoid treatment increases serum IL-13 (75).

We directly assessed for IL-4 signaling in kidney biopsies from MCD patients. Biopsies from untreated MCD patients are difficult to procure, as patients are often initially treated without biopsy, particularly in the United States. Despite this, we identified 29 kidney biopsies of untreated MCD patients, of which 10 had either strongly or weakly positive glomerular staining for activated STAT6. Antibody staining of formalin-fixed paraffin-embedded tissue can be challenging, and we were careful to score only for strong nuclear staining in glomerular nuclei. This was clear-cut in two of our samples, as blindly evaluated by three pathologists independently. In some of the samples (8 of 29 patients, 1 of 22 controls), glomerular nuclear staining was detected, along with weak cytoplasmic staining in glomerular and/or tubular cells. While the cytoplasmic staining likely represents nonspecific background staining, we categorized these samples in a separate group. Importantly, both groups of patients with pSTAT6 staining responded to steroids, consistent with an immune mechanism of disease.

Most of our samples did not show pSTAT6, supporting the heterogeneity of MCD, which may have other causes (76–78), such as CLLCF1 (47) or ANGPTL4 (78). Additionally, while 90% of MCD patients respond to glucocorticoids (79), most of these patients will experience a relapse requiring additional therapy (79, 80). The identification of a subset of patients with MCD due to IL-4 may lead to more personalized and specific therapeutic approaches for the treatment of SSNS. Our work also potentially explains the association of atopy with MCD as well as the efficacy of steroids and rituximab in some patients.

Methods

Reagents. Anti-SMPDL3B polyclonal antibody was purchased from Geneway (catalog GWB-2281D4). Anti-HA (catalog 901501, clone 16B12) antibody, Alexa Fluor 488–conjugated anti-HA (catalog 901509, clone 16B12) antibody, Alexa Fluor 488 IgG1, k isotype control (catalog 400132), and Alexa Fluor 647 mouse IgG2a, k isotype control (catalog 400234) were purchased from Biolegend. Anti-CD20 polyclonal antibody (catalog PA5-16701) was purchased from Thermo Fisher Scientific. Anti–β-actin antibody (catalog A1978, clone AC-15) was purchased from MilliporeSigma. Rituximab was produced in-house by the Antibody Engineering Department at Genentech (81). Alexa Fluor 647–conjugated rituximab was generated using the Alexa Fluor 647 Antibody Labeling Kit (Thermo Fisher Scientific). Recombinant murine IL-13 and TNF-α (Peprotech) and recombinant murine EGF (Cell Signaling Technology) were reconstituted using the manufacturer’s recommendations. Recombinant murine IL-4, IFN-γ, and anti-mouse IL-4 monoclonal antibody (clone 11B11) (82) were gifts from Robert Schreiber, Washington University in St. Louis. FITC-conjugated anti-HEL monoclonal antibody (clone F10.6.6; Emil Unanue, Washington University School of Medicine) (83) and nephrotoxic serum (Jeffrey Kopp, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland, USA) were also provided. FITC-conjugated polyclonal anti-mouse C3 F(ab′)2 fragment (catalog 0855510) was purchased from MP Biomedicals. Anti-pSTAT6 (pTyr641, catalog SAB4300038) polyclonal antibody was purchased from MilliporeSigma. All secondary antibodies used purchased from Jackson ImmunoResearch Laboratories Inc.

Mice. Mice were maintained under specific pathogen–free conditions in the Washington University School of Medicine animal facilities according to institutional animal care guidelines. 129X1/SvJ (catalog 000691), B6.129P2-Ighm<sup>μμμμ</sup>/J (muMT) (84) (catalog 0002288), and B6.129P2-IL4<sup>−/−</sup>/J (IL-4–deficient) (85) (catalog 000225) mice were purchased from Jackson Laboratory. HELmuMT (MD4 line) mice (86) (originally purchased from Jackson Laboratory, catalog 002595) were provided by Emil Unanue. IL-4–deficient HELmuMT mice were generated in two steps: (a) crossing IL-4–knockout mice to muMT mice to produce B cell–deficient, IL-4–deficient mice, and (b) crossing IL-4–deficient, muMT mice with HELmuMT to produce IL-4–deficient mice with HEL-transgenic B cells. All mice used were 6- to 8-week-old females.

Generation of HA-tagged SMPDL3B construct. A mammalian expression construct of human SMPDL3B (pCMV6-XL5 human SMPDL3B transcript variant 1, NM_014474) was purchased from Origene. HA-tag (YPDYVDPDYA) was inserted downstream of the signal peptide (aa 1–18) using the QuickChange II XL site-directed mutagenesis kit (Agilent) according to the manufacturer’s instructions.

Cell culture and transient transfection. 293T cells (catalog CRL-3216, ATCC) and HeLa cells (catalog CCL-2, ATCC) were maintained at 37°C in DMEM supplemented with 10% FBS. 293T cells and HeLa cells were transfected using Lipofectamine 2000 and Lipofectamine 3000 (ThermoFisher), respectively, in
6-well plates at approximately 70% confluency. Conditionally immortalized murine podocyte cell line generation and propagation have been previously described (87, 88). Podocytes were propagated at 33°C (permissive temperature) on collagen-I–coated dishes in RPMI, 10% FBS, and 10 U/ml recombinant mouse IFN-γ. Differentiation was induced by changing media to RPMI, 5% FBS without IFN-γ, and shifting the cells to 37°C (nonpermissive temperature) for at least 7 days. After differentiation, cells arrested their growth, increased size, and developed elongated cell processes.

Western blot. Cells were lysed in a modified RIPA lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, Complete mini protease inhibitor cocktail [Roche]) for 30 minutes on ice. Samples were separated by SDS-PAGE, transferred to nitrocellulose membranes, and immunoblotted for SMPDL3B, HA, CD20, and β-actin. The blots were visualized by infrared imaging on an Odyssey Imaging System (LI-COR Biosciences). To remove glycan groups, samples were treated with PNGase F (New England Biolabs) according to the manufacturer’s instructions prior to SDS-PAGE.

Flow cytometry. The cells were washed with ice-cold PBS and dissociated using a nonenzymatic cell dissociation buffer (Thermo Fisher Scientific). For nonfixed cells, cells were directly resuspended in FACS buffer (2% FBS and 2 mM EDTA in 1× PBS). For fixed cells, cells were incubated in 4% PFA (Electron Microscopy Sciences) in PBS (pH 7.4) for 15 minutes at room temperature, washed 3 times in cold PBS, and then resuspended in FACS buffer. Cells were incubated with Alexa Fluor 488–conjugated anti-HA antibody (0.5 μg/ml) and Alexa Fluor 647–conjugated rituximab (5 μg/ml) for 30 minutes at 4°C. FACS data were collected on a BD LSRII Fortessa flow cytometer (BD Biosciences) and analyzed with FlowJo software (FlowJo).

Light and immunofluorescence microscopy. To confirm membrane localization of HA-SMPDL3B, 293T cells were plated and transfected in Nunc Lab-Tek II CC2 chamber slides (Thermo Fisher Scientific). Cells were fixed with 4% PFA in PBS for 15 minutes at room temperature, washed, and stained with Alexa Fluor 488–conjugated anti-HA antibody (0.5 μg/ml) overnight at 4°C. Coverslips were mounted with ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific), and images were captured with a Nikon A1R confocal microscope. For H&E staining, kidneys were fixed with 10% buffered formalin solution and embedded in paraffin. 5-μm sections were collected and then stained with H&E. Otherwise, kidneys were snap frozen in OCT media and 7-μm sections were collected. For immunofluorescence, sections were stained with primary antibody for 1 hour at room temperature (anti-HEL = 1:250, anti-Ig = 1:200, anti-C3 = 1:200) and treated with the appropriate secondary antibody. Some sections were counterstained with Hoechst dye to visualize nuclei. Coverslips were mounted with ProLong Antifade mounting medium (Invitrogen), and images were captured with an Olympus FluoView FV1000 microscope. For immunohistochemistry, mice were anesthetized and then perfused with 4% PFA (Electron Microscopy Sciences) in PBS (pH 7.4) for 15 minutes at room temperature, washed 3 times in cold PBS, and then resuspended in FACS buffer. Cells were incubated with Alexa Fluor 488–conjugated anti-HA antibody (0.5 μg/ml) overnight at 4°C. Coverslips were collected and then stained with Alexa Fluor 488–conjugated anti-HA antibody (0.5 μg/ml) for 30 minutes at 4°C. FACS data were collected on a BD LSRII Fortessa flow cytometer (BD Biosciences) and analyzed with FlowJo software (FlowJo).

Membrane ruffling assay and kymograph analysis. Murine podocytes were cultured in glass-bottomed dishes at 37°C for 10 days to allow for full differentiation. Eight hours prior to imaging, the cells were washed and cultured in serum-free media to arrest any baseline membrane ruffling. Sequential images were captured by an Olympus FluoView FV1000 microscope every 10 seconds for a 20-minute duration prior to and after cytokine addition. Anti–IL-4 antibody and JAK inhibitor were added to podocytes 1 hour prior to IL-4 addition. Olympus Fluoview software was used to assemble movies. The ImageJ plug-in, Multiple Kymograph (NIH; http://rsbweb.nih.gov/ij), was used to create kymo-
graphs at 5 different locations of maximum membrane ruffling for each cell imaged (89). Ten actin spikes were measured for each kymograph, and average length (ruffling index) was determined as previously described (27).

**Scanning electron microscopy.** For visualizing foot processes in minced renal cortices, kidneys were harvested from 129X1/SvJ mice and placed in media composed of RPMI/F12, 15 mM HEPES, 10 pM PGE₃ (MilliporeSigma), 5 µg/ml transferrin (MilliporeSigma), and 10 nM sodium selenate (MilliporeSigma). The cortex of the kidney was minced using sterile blades and cultured in media with or without cytokine or antibody for 20 minutes at 37°C. The tissue was washed in PBS and then fixed in 0.2 M sodium cacodylate buffer (Electron Microscopy Services) with 2% PFA and 2% glutaraldehyde. Samples were post-fixed in 1% phosphate-buffered osmium tetroxide, dehydrated in graded ethanol, and critical-point dried in carbon dioxide. The samples were mounted onto stubs and then sputter-coated using gold/palladium. For all other scanning electron microscopy images, kidneys were harvested and cortices were diced and processed as described above. Fifteen glomeruli per sample were analyzed using a Hitachi S-2600H scanning electron microscope at the Microscopy and Digital Imaging Core at Washington University in St. Louis.

**Assessment of pSTAT6 staining.** The stratification of pSTAT6 staining (negative, weakly positive, and strongly positive) was based on these criteria: negative — no nuclear staining or no enhanced nuclear staining over background (cytoplasmic); weakly positive — enhanced nuclear staining noticeable over background; and strongly positive — pronounced nuclear staining over background. Two blinded pathologists scored all slides for the presence of pSTAT6 staining.

**Intravital 2-photon microscopy.** The preparation of kidney intravital 2-photon microscopy was adapted from previously described approaches (90–92). Briefly, 8- to 10-week-old mice previously given multimerized HEL were anesthetized with isoflurane and a small vertical incision was made in the flank of the mouse. The kidney was exposed, and an upper chamber plate painted with a thin ring of VetBond tissue adhesive (3M) was gently lowered on to the kidney to secure it to the cover glass and seal the peritoneal cavity. A dual-channel heating system (Warner Instruments) warmed the imaging chamber to 37°C. CFSE-labeled HEL-specific B cells were then transferred by tail vein injection, followed with 2,000 kD Rhodamine dextran to label vessels and glomeruli. Time-lapse imaging was performed using a custom-built 2-photon microscope and ImageWarp acquisition software (A&B Software). Images were acquired either at video rate (30 f/sec) or by time-lapse imaging, where we averaged 15 video-rate frames (0.5 s/slice) creating a Z-stack of 31 sequential Z-steps (2.5 µm each). Each optical section was approximately 220 × 240 µm in the x and y dimensions.

**IL-4 piggyBac plasmid construction, hydrodynamic injection, and tofacitinib administration.** Plasmid encoding murine IL-4 was a gift from Ken Murphy (Washington University in St. Louis). IL-4 was amplified and cloned into the PB530A-2 vector (System Biosciences) using BamHI and NotI. The piggyBac/IL-4 and transposase vectors were prepped using the Qiagen EndoFree Plasmid Maxi Kit and combined at a 5:1 ratio (total DNA = 45 µg) in approximately 2 ml TransIT QR Hydrodynamic Delivery Solution (Mirus Bio). Hydrodynamic injection of these vectors occurred through the tail vein using a 30-gauge needle. Serum IL-4 was determined using the Mouse IL-4 Quantikine ELISA Kit (R&D Systems). For the JAK inhibitor experiments, tofacitinib (Selleckchem) was mixed with 0.5% methylcellulose and 0.025% Tween-20 in water, and 50 mg/kg was administered by oral gavage to mice twice daily.

**Assessment of proteinuria.** For SDS-PAGE analysis, 5 µl urine was loaded with 4 Laemmli sample buffer onto a 4%–20% SDS polyacrylamide gel (Bio-Rad). Proteins were visualized by staining the gel with Coomassie blue. For quantification, the Mouse Albumin ELISA Quantification Set (Bethyl Laboratories Inc.) and QuantiChrom Creatinine Assay Kit (Bioassay Systems) were used using manufacturer’s directions.

**Production of multimerized HEL and injection into mice.** HEL (Amresco) was dissolved in sterile PBS (Hyclone) and treated with NHS-biotin (Thermo Scientific), followed with dialysis using Slide-A-Lyzer Dialysis Cassettes G2 (Thermo Scientific) against sterile PBS. Avidin (Invitrogen) was slowly added to the solution of biotinylated HEL to generate multimerized HEL. The size of multimerized HEL was confirmed using SDS-PAGE, followed by Coomassie blue staining. Multimerized HEL (1 mg) was delivered i.v. via tail vein injection into mice, and organs were harvested 30 minutes to 7 days after infusion.

**HEL-specific B cell isolation, polarization, CFSE labeling, and adoptive transfer into mice.** Spleens from HELmuMT or IL-4–deficient HELmuMT mice were collected into a cell strainer (100-µm nylon mesh) and mashed through. Splenocytes were washed and resuspended in PBS supplemented with 2% FBS...
and 2 mM EDTA. B cells were enriched by negative isolation using the Dynabeads Mouse CD43 (Untouched B cells) Isolation Kit (Invitrogen). B cell purity was validated by flow cytometry (using B220 as the B cell marker), and consistently was >95%. Unpolarized B cells were polarized into IL-4–secreting B cells as previously described (13, 36). Purified HEL-specific B cells were CFSE-labeled per the manufacturer’s instructions (CellTrace CFSE Cell Proliferation Kit, Molecular Probes/Invitrogen). 5 × 10^6 B cells were transferred via tail vein injection into wild-type hosts previously administered multimerized HEL.

**Statistics.** All data, except for pSTAT6 characterization data, are represented as mean ± SD. For membrane ruffling results, group differences were assessed by repeated-measures 1-way ANOVA with Bonferroni correction. For pSTAT6 characterization, Fisher’s exact test was used. For all other results, 2-tailed Mann-Whitney test was used. A *P* value of less than 0.05 was considered significant.

**Study approval.** All animal experiments were conducted with approval from the Washington University in St. Louis Animal Care and Use Committee (St. Louis, Missouri, USA). Patient samples were obtained in a deidentified manner, with institutional review board approval from King’s College/Evelina Children’s Hospital, the Kidney Translational Research Core (Washington University in St. Louis), and the University of Michigan.

**Author contributions**

AHJK designed and performed the experiments, analyzed the experiments, and wrote the manuscript. JJC performed the SMPDL3B experiments and wrote the manuscript. SA designed the experiments, performed the blinded evaluation of pSTAT6 staining on human kidney sections, and edited the manuscript. AK, SJ, and JBH provided human kidney sections. MJM designed and performed the 2-photon microscopy experiments. TSS performed the blinded evaluation of pSTAT6 staining on human kidney sections and edited the manuscript. JHM designed the experiments and edited the manuscript. ASS designed the experiments, participated in data analysis, and wrote and edited the manuscript.

**Acknowledgments**

This work was supported by grants from the Rheumatology Research Foundation (Scientist Development Award and Investigator Award) to AHJK; from the NIH (K08DK088944) and the NephCure-ASN Foundation to JBH; from the NIH (R01DK058366) to ASS; and the Howard Hughes Medical Institute. Patient recruitment and specimen services were supported by the Washington University in St. Louis George M. O’Brien Center for Kidney Translational Research Core (NIH P30 DK079333) and the Renal Division at Washington University in St. Louis. Electron microscopy work was supported in part by the Washington University in St. Louis Microscopy and Digital Imaging Core (NIH P30 DC004665). We appreciate the efforts of Emil Unanue and Ta-Chiang Liu in assisting with the blinded scoring of pSTAT6 staining in the MCD patient slides. We are grateful for the services of the Washington University in St. Louis Kidney Translational Research Core (specifically Kristen Aubuchon and Mary Hoffman for patient recruitment and Amanda Knoten for technical assistance with histology sections from patient biopsies). We acknowledge Yu Tao in the Washington University in St. Louis Research Design and Biostatistics Group for the Institute of Clinical and Translational Sciences for statistical assistance. We thank Jaclynn Lett for electron microscopy sample preparation in the Microscopy and Digital Imaging Core in the Research Center for Auditory and Visual Studies, Department of Otolaryngology, Washington University School of Medicine. We also thank Facundo Batista for assistance with HEL multimerization.

Address correspondence to: Andrey S. Shaw, Genentech, One DNA Way, South San Francisco, California 94080, USA. Phone: 650.225.2367; Email: shaw.andrey@gene.com.

SA’s present address is: Department of Pathology, University of Washington, Seattle, Washington, USA.

MJM’s present address is: Division of Infectious Disease, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.

JJC and ASS’s present address is: Genentech, South San Francisco, California, USA.
34. Harris DP, Goodrich S, Mohr K, Mohr M, Lund FE. Cutting edge: the development of IL-4 producing B cells (B effector 2 cells) is controlled by IL-4, IL-4 receptor alpha, and Th2 cells. *J Immunol*. 2005;175(11):7103–7107.


